BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target Raised to $29.00 at HC Wainwright

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its target price upped by investment analysts at HC Wainwright from $27.00 to $29.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 193.23% from the stock’s previous close.

A number of other research firms have also weighed in on BBOT. Stifel Nicolaus started coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective for the company. Weiss Ratings started coverage on shares of BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. Finally, Raymond James Financial raised shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

Shares of BBOT stock opened at $9.89 on Friday. The company has a market capitalization of $791.09 million, a P/E ratio of -9.60 and a beta of 0.28. BridgeBio Oncology Therapeutics has a 12-month low of $8.50 and a 12-month high of $14.87.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Several institutional investors have recently modified their holdings of BBOT. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $63,000. Persistent Asset Partners Ltd purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter valued at $144,000. Quadrature Capital Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at $162,000. Finally, BIT Capital GmbH bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth about $313,000. 54.89% of the stock is owned by institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.